Biotech Stocks Touched New Lows: Rock Creek Pharmaceuticals (NASDAQ:RCPI), Medgenics (NYSEMKT:MDGN), BIND Therapeutics (NASDAQ:BIND), NeuroDerm (NASDAQ:NDRM), Regado Biosciences (NASDAQ:RGDO)


Rock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI) on Nov. 10 announced its financial results for the third quarter ended September 30, 2014 and provided a business update. The Company recorded a net loss of approximately $10.0 million for the three months ended September 30, 2014, compared to a net loss of approximately $3.4 million for the same period in 2013. For the three months ended September 30, 2014, the Company had a basic and diluted loss per share of $(0.05), compared to a basic and diluted loss per share of $(0.02) for the comparable period in 2013. Rock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI) in last trading activity advanced 3.23% to close at $0.16. Company weekly performance is -5.88% while its quarterly performance stands at -52.94%. Rock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI) is -88.73% away from its 52 week high.

Medgenics, Inc.(NYSEMKT:MDGN) announced the pricing of 5,125,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $4.10 per share. In connection with the offering, Medgenics has also granted the underwriters a 30-day option to purchase up to an additional 768,750 shares of its common stock. Gross proceeds to Medgenics from the sale of shares are expected to be approximately $21.0 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. If the underwriters’ option is exercised in full, gross proceeds will be $24.2 million. The offering is expected to close on or about December 1, 2014 subject to customary closing conditions. On last trading day Medgenics, Inc. (NYSEMKT:MDGN) fell -10.67% to close at $4.27. Its volatility for the week is -28.71% while volatility for the month is 6.64%. MDGN’s EPS growth for past 5 years was 10.00%. Medgenics, Inc. (NYSEMKT:MDGN) monthly performance is -12.68%.

BIND Therapeutics, Inc., (NASDAQ:BIND) a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, on 20 November presented positive results from its ongoing Phase 2 study of BIND-014 in non-small cell lung cancer (NSCLC), demonstrating it has met the primary objective in the once every three weeks (Q3W) arm as measured by overall response rate (ORR). On last trading day BIND Therapeutics, Inc. (NASDAQ:BIND) fell -3.28% to close at $6.79. Its volatility for the week is 13.03% while volatility for the month is 8.48%. BIND Therapeutics, Inc. (NASDAQ:BIND) monthly performance is -11.93%.

NeuroDerm Ltd., (NASDAQ:NDRM) a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, on 3 November announced the launch of its initial public offering of 4,500,000 ordinary shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC). NeuroDerm has applied to list its ordinary shares on the Nasdaq Global Market under the ticker symbol “NDRM.” NeuroDerm Ltd. (NASDAQ:NDRM) stock closed at $7.15.

On 5 November Regado Biosciences, Inc. (NASDAQ:RGDO) announced net loss for the quarter ended September 30, 2014, was $21.1 million, or a net loss of $.59 per share, as compared to a net loss of $11.4 million, or a net loss of $1.43 per share, for the corresponding period in 2013 on both a basic and fully diluted basis. On Tuesday shares of Regado Biosciences, Inc. (NASDAQ:RGDO) closed at $0.83.


Leave a Reply

Your email address will not be published. Required fields are marked *